SCHEMBL23799092

SCHEMBL23799092

COc1cc(-c2cn(C)c(=O)c3[nH]ncc23)cc(OC)c1CN1CCN(C)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 9/20 0.45
BRD7 Q9NPI1 7/20 0.45
TGFBR1 P36897 2/20 0.45
ACVR1 Q04771 2/20 0.45
TAF1 P21675 1/20 0.45
BRPF1 P55201 1/20 0.45
BPTF Q12830 1/20 0.45
TAF1L Q8IZX4 1/20 0.45
CREBBP Q92793 1/20 0.45
CECR2 Q9BXF3 1/20 0.45
BAZ2B Q9UIF8 1/20 0.45
ATAD2B Q9ULI0 1/20 0.45
BRD4 O60885 10/20 0.44
BRD2 P25440 2/20 0.44
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MAP4K1 Q92918 1/20 0.39
KDR P35968 1/20 0.37
GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23798972 0.93 BRD4 (0.42) BRD9BRD7TGFBR1ACVR1TAF1
SCHEMBL23783026 0.92 BRD9 (0.44) BRD9BRD7TGFBR1ACVR1TAF1
SCHEMBL23798862 0.90 BRD9 (0.43) BRD9BRD7TGFBR1ACVR1TAF1
SCHEMBL25091959 0.90 BRD9 (0.43) BRD9BRD7TGFBR1ACVR1TAF1
SCHEMBL25852361 0.90 BRD9 (0.41) BRD9BRD7TGFBR1ACVR1TAF1
SCHEMBL25091533 0.88 BRD4 (0.46) BRD9BRD7TGFBR1ACVR1TAF1
SCHEMBL23798716 0.88 BRD4 (0.42) BRD9BRD7TGFBR1ACVR1TAF1
SCHEMBL25844172 0.88 BRD4 (0.43) BRD9BRD7TGFBR1ACVR1TAF1
SCHEMBL25091527 0.86 BRD9 (0.46) BRD9BRD7TGFBR1ACVR1TAF1
SCHEMBL25852139 0.86 BRD9 (0.41) BRD9BRD7TGFBR1ACVR1TAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
WO-2021178920-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2021-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 BRD9 1/4885BRD7 7/4885TGFBR1 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.